文献速递炎症性肠病

局部Rho激酶抑制剂通过多效作用治疗实验性炎症性肠病肠纤维化

Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor.
PubMed 文献 · Gastroenterology · 2017-06-19

该研究在DSS和T细胞过继转移小鼠模型中评估局部Rho激酶抑制剂AMA0825对肠纤维化的作用,并在CD活检培养中验证。结果显示局部ROCK抑制可预防并逆转纤维化,机制涉及降低MRTF和p38 MAPK活化、增强成纤维细胞自噬,且不影响炎症活动,作者认为有望作为CD的抗纤维化附加治疗。

要点

  • 局部ROCK抑制剂AMA0825在两种小鼠纤维化模型中预防肌成纤维细胞积聚和促纤维化因子表达,且不影响临床疾病活动度和组织学炎症。
  • 在慢性DSS模型中AMA0825可逆转已建立的纤维化,并抑制狭窄性CD活检的促纤维化蛋白分泌。
  • 机制上,AMA0825降低TGFβ1诱导的MRTF和p38 MAPK活化,下调基质金属蛋白酶、胶原和IL6分泌,并增强成纤维细胞自噬。

核心结论

  • 局部ROCK抑制通过减少成纤维细胞MRTF和p38 MAPK活化并增加自噬,预防并逆转肠纤维化。
  • 作者认为局部ROCK抑制有望作为CD的抗纤维化附加治疗。

研究设计与样本

  • 研究使用DSS和过继T细胞转移小鼠模型评估纤维化,并在不同细胞类型和CD活检培养中研究AMA0825的体外和离体效应。

主要发现

  • ROCK在人肠道成纤维细胞、上皮细胞、内皮细胞和肌肉细胞中表达,并在炎症和纤维化组织中活化。
  • 在2种纤维化模型中,预防性AMA0825治疗抑制肌成纤维细胞积聚、促纤维化因子表达和纤维化组织积聚,且不影响临床疾病活动度和组织学炎症。
  • 在慢性DSS模型中ROCK抑制逆转已建立的纤维化,并阻碍狭窄性CD活检的离体促纤维化蛋白分泌。
  • AMA0825降低TGFβ1诱导的MRTF和p38 MAPK活化,下调成纤维细胞基质金属蛋白酶、胶原和IL6分泌。
  • 在成纤维细胞中ROCK抑制增强自噬,而自噬是观察到的胶原和IL6产生减少所必需的;AMA0825不影响其他ROCK阳性细胞类型的促炎细胞因子分泌。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intestinal fibrosis resulting in (sub)obstruction is a common complication of Crohn's disease (CD). Rho kinases (ROCKs) play multiple roles in TGFβ-induced myofibroblast activation that could be therapeutic targets. Because systemic ROCK inhibition causes cardiovascular side effects, we evaluated the effects of a locally acting ROCK inhibitor (AMA0825) on intestinal fibrosis. METHODS: Fibrosis was assessed in mouse models using dextran sulfate sodium (DSS) and adoptive T-cell transfer. The in vitro and ex vivo effects of AMA0825 were studied in different cell types and in CD biopsy cultures. RESULTS: ROCK is expressed in fibroblastic, epithelial, endothelial, and muscle cells of the human intestinal tract and is activated in inflamed and fibrotic tissue. Prophylactic treatment with AMA0825 inhibited myofibroblast accumulation, expression of pro-fibrotic factors, and accumulation of fibrotic tissue without affecting clinical disease activity and histologic inflammation in 2 models of fibrosis. ROCK inhibition reversed established fibrosis in a chronic DSS model and impeded ex vivo pro-fibrotic protein secretion from stenotic CD biopsies. AMA0825 reduced TGFβ1-induced activation of myocardin-related transcription factor (MRTF) and p38 mitogen-activated protein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion from fibroblasts. In these cells, ROCK inhibition potentiated autophagy, which was required for the observed reduction in collagen and IL6 production. AMA0825 did not affect pro-inflammatory cytokine secretion from other ROCK-positive cell types, corroborating the selective in vivo effect on fibrosis. CONCLUSIONS: Local ROCK inhibition prevents and reverses intestinal fibrosis by diminishing MRTF and p38 MAPK activation and increasing autophagy in fibroblasts. Overall, our results show that local ROCK inhibition is promising for counteracting fibrosis as an add-on therapy for CD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Holvoet T, Devriese S, Castermans K, et al. Treatment of Intestinal Fibrosis in Experimental Inflammatory Bowel Disease by the Pleiotropic Actions of a Local Rho Kinase Inhibitor. Gastroenterology. 2017. PMID: 28642198. doi:10.1053/j.gastro.2017.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。